Stock AnalizBoston Scientific Corp. BSX
Medical/Dental Instruments · data as of November 13, 2026
Boston Scientific Corp. (BSX) is a healthcare company listed in the US with a market value of about $64.3B. In the twelve months to September 30, 2026 it had revenue of $21.1B and net income of $3.5B, a net margin of 16.6%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is future growth (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 18.8, a price to free cash flow of 19.3, 5-year revenue growth of 15% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 58% below the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- Debt below 3 years of free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.1B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $9.1B |
| Net income | $3.5B | $2.9B | $1.9B | $1.6B | $642M | $985M | -$115M | $4.7B | $1.7B | $104M | $347M |
| Free cash flow | $3.3B | $3.7B | $2.6B | $1.8B | $938M | $1.3B | $1.1B | $1.4B | -$6M | $1.1B | $806M |
| EPS (diluted) | $2.36 | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 | $3.33 | $1.19 | $0.08 | $0.25 |
| Net margin | 16.6% | 14.4% | 11.1% | 11.0% | 5.1% | 8.3% | -1.2% | 43.8% | 17.0% | 1.1% | 3.8% |
| ROIC | — | 8.5% | 6.4% | 6.5% | 3.8% | 4.4% | -0.2% | 5.0% | 7.5% | 8.0% | 2.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 28 analysts is $49.60, 12% above the current price; targets range from $41.00 to $60.00; the consensus rating is “Buy”; expected EPS is $3.17 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Boston Scientific’s P/E ratio?
About 18.8, based on the last twelve months of diluted earnings per share (forward P/E about 14.4).
Is Boston Scientific stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 58% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Boston Scientific pay a dividend?
Not currently.
Is Boston Scientific a good stock to buy?
We do not give buy or sell advice. Boston Scientific scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.